2026 Marcus Neuroscience Institute Brain and Spine Symposium Evaluation - Day 1

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence Not applicable|Not applicable

	5	4	3	2	1	Not applicable
Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety.	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - 5	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - 4	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - 3	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - 2	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - 1	Describe how augmented reality guidance systems can be used to increase intraoperative accuracy, advance minimally invasive surgeries and improve patient safety. - Not applicable
Explain the role of a comprehensive multimodal team approach in the management of postoperative pain.	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - 5	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - 4	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - 3	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - 2	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - 1	Explain the role of a comprehensive multimodal team approach in the management of postoperative pain. - Not applicable
Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors.	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - 5	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - 4	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - 3	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - 2	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - 1	Discuss essential tremors and the use of high-intensity focused ultrasound to manage tremors. - Not applicable
Describe the role of neuropsychological testing in neurological patients.	Describe the role of neuropsychological testing in neurological patients. - 5	Describe the role of neuropsychological testing in neurological patients. - 4	Describe the role of neuropsychological testing in neurological patients. - 3	Describe the role of neuropsychological testing in neurological patients. - 2	Describe the role of neuropsychological testing in neurological patients. - 1	Describe the role of neuropsychological testing in neurological patients. - Not applicable
Identify new medications for epilepsy patients and updates of epilepsy management.	Identify new medications for epilepsy patients and updates of epilepsy management. - 5	Identify new medications for epilepsy patients and updates of epilepsy management. - 4	Identify new medications for epilepsy patients and updates of epilepsy management. - 3	Identify new medications for epilepsy patients and updates of epilepsy management. - 2	Identify new medications for epilepsy patients and updates of epilepsy management. - 1	Identify new medications for epilepsy patients and updates of epilepsy management. - Not applicable

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - 5	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - 4	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - 3	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - 2	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - 1	Brave New World 2026: Artificial Intelligence (AI) and the Future of Neuroscience - Deepak S. Nair, M.D., MBA - NA
Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - 5	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - 4	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - 3	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - 2	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - 1	Alzheimer's Disease Infusion Treatment - G. Peter Gliebus, M.D., FAAN - NA
Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - 5	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - 4	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - 3	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - 2	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - 1	Neurosyphilis: Overview and Update - Sunil M. Chauhan, M.D., MsPH, FAAN - NA
Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - 5	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - 4	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - 3	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - 2	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - 1	Lewy Body Disorders Across the Spectrum: Clinical Recognition, Biomarkers, and Management of DLB and PDD - G. Peter Gliebus, M.D., FAAN - NA
Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - 5	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - 4	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - 3	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - 2	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - 1	Neurotoxins: The Elephant in the Room - Raphael Wald, Psy.D., ABN, CMPC - NA
Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - 5	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - 4	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - 3	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - 2	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - 1	Temperature Inversion: A Pathognomonic Symptom of Ciguatera Toxic Neuropathy - Marc A. Swerdloff, M.D., ABPN, FANA - NA
Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O.	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - 5	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - 4	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - 3	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - 2	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - 1	Stroke is Changing: Epidemiology We Need to Talk About -- Constance V. Katsafanas, D.O. - NA
Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - 5	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - 4	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - 3	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - 2	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - 1	Extended Window for Thrombolysis in AIS - Felipe De Los Rios La Rosa, M.D., FAHA - NA
Depression and Stroke - Yankel Girshman, D.O., DFAPA	Depression and Stroke - Yankel Girshman, D.O., DFAPA - 5	Depression and Stroke - Yankel Girshman, D.O., DFAPA - 4	Depression and Stroke - Yankel Girshman, D.O., DFAPA - 3	Depression and Stroke - Yankel Girshman, D.O., DFAPA - 2	Depression and Stroke - Yankel Girshman, D.O., DFAPA - 1	Depression and Stroke - Yankel Girshman, D.O., DFAPA - NA
Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D.	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - 5	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - 4	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - 3	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - 2	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - 1	Idiopathic Intracranial Hypertension: New Metabolic Drivers and Evolving Treatments - Pablo Ravenna, M.D. - NA
Epilepsy and Pregnancy - Pooja Sureja Patel, M.D.	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - 5	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - 4	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - 3	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - 2	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - 1	Epilepsy and Pregnancy - Pooja Sureja Patel, M.D. - NA
Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - 5	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - 4	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - 3	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - 2	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - 1	Primary Headache Phenotype: The Follow-up Visit - Jacklynn S. Green, APRN, MSN, FNP-BC - NA
Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - 5	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - 4	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - 3	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - 2	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - 1	Determining Brain Death: Pearls and Pitfalls - Deepak S. Nair, M.D., MBA - NA
Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - 5	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - 4	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - 3	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - 2	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - 1	Approaching the Weak Patient: Strategies for Diagnosing Myasthenia Gravis - Svetlana Faktorovich, M.D., FAAN - NA
Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O.	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - 5	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - 4	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - 3	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - 2	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - 1	Learning About Essential Tremor: The Diagnosis Process and Treatment Options -Sameea Husain Wilson, D.O. - NA
Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - 5	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - 4	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - 3	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - 2	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - 1	Managing Advanced Parkinson’s Disease - Diego R. Torres-Russotto, M.D., FAAN, FPRD - NA
Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D.	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - 5	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - 4	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - 3	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - 2	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - 1	Spinal Cord Injury, Determining Degree of Injury and Functional Potential - Marcalee S. Alexander, M.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will be able to identify emerging innovations transforming brain and spine care.

I will be able to identify updates to common neurological disorders such as epilepsy, dementia, and multiple sclerosis.

I will discuss interventions and research regarding neurological disorders.

I will be able to describe the differences between cortical and subcortical dementia and identify new diagnostics and treatments for dementia.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

What, if any, new skills/strategies will you apply in your clinical practice? *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

You are here

2026 Marcus Neuroscience Institute Brain and Spine Symposium Evaluation - Day 1